Tag: Sleep Therapy

  SAN DIEGO – As Lucile Blaise takes on a larger role at ResMed, she is prioritizing, among other things, advocating for new forms of reimbursement for digital health.  Here’s what Blaise, who was promoted from ResMed’s vice president of Sleep & Respiratory Care for Western Europe to president of its global business this summer, had to say about why everyone wins when sleep apnea is diagnosed and treated.  HME News: CEO Mick Farrell often talks about the...

NASHVILLE, Tenn. – SleepRes has entered the sleep therapy market with V̇-Com, a device that softens peak inspiratory flow to make CPAP devices more comfortable and increase adherence. “This may be the most important comfort factor in the PAP circuit since we developed BiPAP over 30 years ago,” said Eugene Scarberry, retired senior staff engineer at Philips Respironics for 35 years. “At the end of the day it is all about adherence and the V̇-Com is a whole new approach to...

SAN DIEGO – ResMed reported revenue increased 12% to $864.5 million in its third quarter fiscal year 2022. The company reported revenue, excluding software-as-a-service, increased 18% in the United States, Canada and Latin America, primarily due to a recall by one of its competitors and a recovery of core sleep patient flow that has been impacted by the COVID-19 pandemic. “Our third-quarter results reflect strong performance across our business, resulting in double-digit top-line...

AMSTERDAM, the Netherlands – Philips’ comparable sales decreased 32% in the fourth quarter of 2021 for the Connected Care business due, in part, to a double-digit decline in Sleep & Respiratory Care associated with the recall.  For the full year, the Connected Care business recorded a 23% comparable sales decrease.  “Patient well-being is at the heart of everything we do at Philips, and we remain extremely focused on repairing and replacing the devices related to...

FORT WORTH, Texas – AppYea has acquired SleepX and its flagship product DreamIT, a wearable monitoring solution to treat sleep apnea and snoring. Post-merger, the two companies will focus on the further development and commercialization of SleepX’s solution, including investments in R&D and sales and marketing, as well as an upcoming calibration trial. “I am delighted that we have completed the acquisition of SleepX,” said Boris (Bary) Molchadsky, AppYea’s chairman....

MADISON, Wis. – Bleep has been awarded a $1.7 million SBIR grant from the National Institutes of Health to optimize positive airway pressure mask design for use in the home and acute care/hospital settings. The company will use the grant to optimize its Eclipse PAP, which focuses on having no headgear or straps and addressing leaks, and produce the validation data necessary for successful market commercialization. “Eclipse, our generation two product, will not only continue to address...

AUCKLAND, New Zealand – Fisher & Paykel Healthcare reported total operating revenue of $900 million for the first six months ended Sept. 30, 2021, a 1% decrease compared to the same period the previous financial year.  Net profit after tax was $222 million, a 2% decrease.  “For nearly two years now, our customers have been working selflessly to care for patients during a pandemic,” said Lewis Gradon, managing director and CEO. “Our people and suppliers have...

SAN DIEGO – ResMed reported revenue of $904 million for the first quarter of its fiscal year 2022, a 20% increase compared to the prior year period.  Net income was $203.6 million, a 14% increase.  “Our first-quarter results demonstrate strong performance across our business with double-digit growth in both top-line and bottom-line metrics, driven by ongoing high demand for our sleep and respiratory care products, and steady growth across our software-as-a-service business,”...

BRISBANE, Australia – Oventus Medical has reapplied to Palmetto GBA, the pricing data analysis and coding contractor (PDAC), for approval of the newly submitted Optima version of its O2Vent oral appliance to treat obstructive sleep apnea. This version of the device is designed specifically for Medicare patients. “In the meantime, this means that O2Vent Optima will not be able to be supplied to Medicare patients in its own right for reimbursement purposes,” the company stated....

BRISBANE, Australia – Oventus Medical booked revenues of $1.1 million for the 12 months ended June 30, an increase of 160% over the prior period. “FY21 was Oventus’ best year for device sales on record, despite what remained a highly challenging patient treatment environment for in-person clinical settings, which were heavily tampered by the COVID-19 pandemic,” the company stated. Contributing to Oventus’s growth in the year: lab-in-lab sites that remained operational...